Lymphocyte-macrophage colonization in various molecular biological types of endometrial cancer: comparison with the receptor status and proliferative activity of tumor tissue

ORIGINAL ARTICLES. C. CLINICAL RESEARCH

https://doi.org/10.37469/0507-3758-2021-67-3-405-410

Published 06.07.2021

Lev Bershtein
Aleksandr Ivantsov
Aglaia Ievleva
Dmitrii Vasilev
Igor` Berlev

Lev Bershtein

Aleksandr Ivantsov

Aglaia Ievleva

Dmitrii Vasilev

Igor` Berlev

pdf (Русский)

Keywords

endometrial cancer
molecular-biological types
features

How to Cite

Bershtein, L., Ivantsov , A., Ievleva , A., Vasilev , D., & Berlev, I. (2021). Lymphocyte-macrophage colonization in various molecular biological types of endometrial cancer: comparison with the receptor status and proliferative activity of tumor tissue. Voprosy Onkologii, 67(3), 405–410. https://doi.org/10.37469/0507-3758-2021-67-3-405-410

Abstract

Recent years have been marked by a gradual shift from the previous division of endometrial cancer (EC) into two main types to modern molecular biological classifications of this disease, one of which (at present, most likely, the most popular: Talhouk et al., 2017, 2019) is based on the use of a combination of genetic and immunohistochemical analysis.

The study involved material from untreated EC patients, the number of which varied depending on the method used. The average age of patients was close to 55-60 years, and over 80% of patients were postmenopausal.

Deparaffinized blocks of EC tissue were analyzed for POLE (DNA polymerase epsilon) mutations, evaluated by immunohistochemistry (IHC) the expression of the oncoprotein p53 and MMR (mismatch-repair) proteins / MLH1, MSH2, MSH6 and PMS2 /, and also helped to identify the type of disease without a characteristic molecular profile (WCMP).

In addition to studying the expression of p53 and MMR proteins, the IHC method was also used to study the expression of estrogen (ER) and progesterone (PR) receptors, the Ki-67 proliferative activity index, and the severity of macrophage-lymphocytic infiltration of the EC tissue based on the analysis of the macrophage marker (CD68) and markers of lymphocytic cells (cytotoxic CD8 and regulatory FoxP3) using reagents from Ventana and Dako.

https://doi.org/10.37469/0507-3758-2021-67-3-405-410

pdf (Русский)

References

Talhouk A, McConechy MK, Leung S et al. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017;123(5):802-813. https://doi: 10.1002/cncr.30496.

Берштейн Л.М., Порошина Т.Е., Васильев Д.А., Коваленко И.М. Иванцов А.О., Иевлева А.Г., Берлев И.В. Сравнительные особенности состояния углеводного обмена и массы тела при различных молекулярно-биологических типах рака эндометрия. Вопр. онкол, 2018;64(3):394-398.

Берштейн Л.М., Иевлева А.Г., Иванцов А.О., Васильев Д.А., Клещев М.А., Порошина Т.Е., Коваленко И.М., Венина А.Р., Берлев И.В. Современные молекулярно-биологические типы рака эндометрия: сравнительная эндокринная и провоспалительно-прогенотоксическая характеристика. Вопр. онкол. 2019;65(2):272-278.

Berstein LM, Iyevleva AG, Ivantsov AO, Vasilyev DA, Poroshina TE, Berlev IV. Endocrinology of obese and nonobese endometrial cancer patients: is there role of tumor molecular-biological type? Future Oncol. 2019;15(12):1335-1346. https://doi: 10.2217/fon-2018-0687.

Берштейн Л.М., Иванцов А.О., Иевлева А.Г., Венина А.Р., Берлев И.В. Рецепторный фенотип, экспрессия HER-2/neu, PD1, PDL-1 и лимфоцитарно-макрофагальная инфильтрация карцином эндометрия: сравнение современных молекулярно-биологических типов заболевания (Роль индекса массы тела). Вопр. онкол. 2020;66(1):71-78.

Dun EC, Hanley K, Wieser F, Bohman S, Yu J, Taylor RN. Infiltration of tumor-associated macrophages is increased in the epithelial and stromal compartments of endometrial carcinomas. Int J Gynecol Pathol. 2013;32(6):576-584. https://doi: 10.1097/PGP.0b013e318284e198.

Talhouk A, Derocher H, Schmidt P, Leung S, Milne K, Gilks CB et al. Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma. Clin Cancer Res. 2019;25(8):2537-2548. https://doi: 10.1158/1078-0432.CCR-18-3241.

de Jong RA, Leffers N, Boezen HM, ten Hoor KA, van der Zee AG, Hollema H, Nijman HW. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol. 2009;114(1):105-110.

Eggink FA, Van Gool IC, Leary A, Pollock PM, Crosbie EJ, Mileshkin L, Bosse T. et al. Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. Oncoimmunology. 2016;6(2):e1264565.

Gadducci A, Guerrieri ME. Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research. Anticancer Res. 2017;37(11):5955-5965.

Szylberg Ł, Karbownik D, Marszałek A. The Role of FOXP3 in Human Cancers. Anticancer Res. 2016;36(8):3789-3794.

Kitson S, Sivalingam VN, Bolton J, Crosbi E J. Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies. Mod.Pathol. 2017;30(3),459-468.

Stelloo E, Jansen AML, Osse EM et al. Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Ann Oncol. 2017;28(1):96-102.

Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17(5):1474-1481.

Łapińska-Szumczyk SM, Supernat AM, Majewska HI, Gulczyński J, Biernat W, Wydra D, Żaczek AJ. Immunohistochemical characterisation of molecular subtypes in endometrial cancer. Int J Clin Exp Med. 2015;8(11):21981-21990.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.